Sentences with phrase «pulmonary fibrosis in»

It is for his more last attributes, however, that Coughlin is being best remembered, after succumbing to a rare form of pulmonary fibrosis in July.

A condition called pulmonary fibrosis in which the tissue of the lungs becomes scarred and rigid, interferes with the ability to breath properly and extract oxygen from the air.

In a collaborative study published in Nat Med, a Fleming Marie Curie Fellow revealed that aerosolized delivery of active Thyroid Hormone (TH) resolved pulmonary fibrosis in two mouse models through a mechanism that involved improvement of mitochondrial biogenesis and mitophagy in alveolar type II epithelial cells.

«Radial Basis Function neural networks classification for the recognition of idiopathic pulmonary fibrosis in microscopic images»

Treatment with plerixafor prevents pulmonary fibrosis in bleomycin - induced murine pulmonary fibrosis.

As a physician who treats patients with pulmonary fibrosis in a multidisciplinary clinic at Jefferson, the research has a sense of urgency.

«Study finds cause of pulmonary fibrosis in failure of stem cells that repair lungs.»

The researchers used mouse models that mimic the disease characteristics of pulmonary hypertension and pulmonary fibrosis in humans to study the effect of triciribine, which inhibits production of a protein called Akt1.

InterMune said Health Canada approved Esbriet as a treatment for mild - to - moderate idiopathic pulmonary fibrosis in adults.

Not exact matches

The 79 - year - old Bright has limited his public appearances and interviews because of pulmonary fibrosis, a debilitating condition that doctors confirmed in October and say give him only a few more years to live.

Childhood asthma, cystic fibrosis, chronic lung disease of infancy, pulmonary problems in children with primary immunodeficiencies

In lieu of flowers, contributions may be made to Pulmonary Fibrosis Foundation, 1440 W. Washington Blvd., Chicago, IL 60607.

In lieu of flowers, memorial contributions may be given to the Pulmonary Fibrosis Foundation, 1332 N. Halsted, Chicago, IL 60642.

A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Like Gilead, which aims to develop treatments for HIV / AIDS, hepatitis B and C, influenza, pulmonary arterial hypertension, and cystic fibrosis, other top employers accentuate the positive aspects of the life science industry by performing their R&D in entirely new areas.

«Master» protein identified in pulmonary fibrosis.»

In AE, widespread lung injury is superimposed on the pulmonary fibrosis, which frequently occurs before patients die.

Four years ago, she was diagnosed with pulmonary fibrosis, a condition that causes scarring in the lungs and results in increasing shortness of breath.

Although no definitive cause for the disease has been identified, pulmonary fibrosis affects nearly 130,000 people in the U.S., with about 48,000 new cases diagnosed annually, according to the Coalition for Pulmonary pulmonary fibrosis affects nearly 130,000 people in the U.S., with about 48,000 new cases diagnosed annually, according to the Coalition for Pulmonary Ffibrosis affects nearly 130,000 people in the U.S., with about 48,000 new cases diagnosed annually, according to the Coalition for Pulmonary Pulmonary FibrosisFibrosis.

Their findings, reported in Nature Communications, may shed light on human lung disease, in particular, the mechanism behind non-familial pulmonary hypertension in patients with conditions such as emphysema and pulmonary fibrosis.

About 50,000 people in the United States annually develop idiopathic pulmonary fibrosis, a progressive disease that principally affects the elderly, according to the Pulmonary Fibrosis Fopulmonary fibrosis, a progressive disease that principally affects the elderly, according to the Pulmonary Fibrosis Foufibrosis, a progressive disease that principally affects the elderly, according to the Pulmonary Fibrosis FoPulmonary Fibrosis FouFibrosis Foundation.

Approximately one in 20 people have a close relative with the disease, in which case they are considered to have familial pulmonary fibrosis.

Researchers at UT Southwestern Medical Center have identified mutations in two genes that cause a fatal lung scarring disease known as familial pulmonary fibrosis.

Further, in laboratory mice, the team found that by deleting this substance, they could produce the type of scarring found in pulmonary fibrosis after lung injury.

The disease often is called idiopathic pulmonary fibrosis because, in most cases, the cause can not be found.

The study is a major step toward understanding and one day treating pulmonary fibrosis, which affects about 100,000 people in the U.S..

In people with pulmonary fibrosis, something goes wrong with AEC2 cells, the study found.

Experts agree the treatment is transformative for patients with the Cheevers» form of CF. «We have just started using it in practice,» says Henry Dorkin, a pediatric pulmonary specialist and director of the Cystic Fibrosis Center at Children's Hospital in Boston.

Pulmonary fibrosis, an ongoing process of scarring that leaves patients chronically short of breath, can progress in severity until the only course of treatment is lung transplant.

In the converse experiment, the group showed that when increasing lipid production in lungs of animals already injured and developing pulmonary fibrosis, lung scarring could be reduced by 70 - 80 percenIn the converse experiment, the group showed that when increasing lipid production in lungs of animals already injured and developing pulmonary fibrosis, lung scarring could be reduced by 70 - 80 percenin lungs of animals already injured and developing pulmonary fibrosis, lung scarring could be reduced by 70 - 80 percent.

Dr. Summer and colleagues are currently working to develop a therapy that could restore lipid production in the lungs of pulmonary fibrosis patients and slow the fibrotic process.

In mouse models, miR - 29 not only blocked pulmonary fibrosis, it reversed fibrosis after several days.

Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

Pulmonary fibrosis causes the patient's lung tissue to scar, resulting in progressive pulmonary function deterPulmonary fibrosis causes the patient's lung tissue to scar, resulting in progressive pulmonary function deterpulmonary function deterioration.

A new study shows that restoring the lipids that help keep lung tissue flexible and inflated can help slow disease progression in laboratory models of pulmonary fibrosis.

Pulmonary fibrosis is a progressive scarring of the lungs, in which the lung walls become so thick and stiff they can no longer transfer oxygen into the bloodstream.

The research team included Scott H. Randell, Ph.D., a leading expert in the culture of primary lung cells, from the Cystic Fibrosis / Pulmonary Research and Treatment Center at the University of North Carolina at Chapel Hill.

Background: * Pulmonary fibrosis is a chronic lung disease, characterized by pathological accumulation of ECM proteins, which results in hardening of the lung and thus difficulties to breathe.

The hedgehog system machinery controls transforming growth factor - ß - dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis.

The Division of Pulmonary Medicine deals with the breath of life in all its aspects: control of breathing; sleep disorders; obstruction to airflow in the common diseases of upper and lower airways such as croup, bronchiolitis, asthma, cystic fibrosis, and bronchopulmonary dysplasia; restriction to lung function from disorders affecting the chest wall, the musculature, the nervous system, or lung tissue itself; congenital anomalies; accidents such as inhalation of foreign bodies, hydrocarbons, or toxic gases; secondary effects of non-pulmonary system disorders such as gastrointestinal reflux, myopathy, or cardiac dysfunction; disease of the upper respiratory tract including rhinitis and sinusitis; and so on.

The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies — Fastrès Aline, International Journal of Molecular Sciences

Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.

April 17, 2013 Gene study helps understand pulmonary fibrosis A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death.

Recent work by Fleming researchers uncovered a protein methylation - dependent control mechanism in the pathogenesis of pulmonary fibrosis.

Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G, Tsiambas E, Karameris A, Bouros D and Aidinis V., 2007, «Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia - inducible factor - 1alpha in disease pathogenesis», Am J Respir Crit Care Med, 176 (11): 1108 - 19 [Pubmed]

«Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia - inducible factor - 1alpha in disease pathogenesis»

The general approach we adopt is to investigate pulmonary fibrosis at the molecular level, in cells and animal models, and to validate the newly - discovered pathways using patient samples.

Personalised medicine is becoming relevant in the treatment of lung cancer [42, 43] and may have relevance for other lung diseases, like pulmonary fibrosis, asthma and pulmonary hypertension, but disease - related basic research aimed at searching for biomarkers is needed to achieve personalised and patient - specific treatments for lung diseases.

Development of inhibitors of metabolic pathways to block oncogenes or signalling molecules in malignant processes and specific inflammatory processes, such as pulmonary artery hypertension or idiopathic pulmonary fibrosis.

New biological treatments using antibodies or antagonists against receptors or inflammatory enzyme inhibitors (e.g. CXCR2 antagonists, phosphodiesterase - 4 inhibitors, endothelin receptor antagonists and kinase inhibitors) to suppress inflammatory pathways in diseases such as asthma, COPD, idiopathic pulmonary fibrosis, cystic fibrosis and pulmonary hypertension.